Reata Pharmaceuticals, Inc. (RETA) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Plano, TX, United States. Le PDG actuel est J. Warren Huff.
RETA a date d'introduction en bourse 2016-05-26, 321 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $6.57B.
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for serious and life-threatening diseases. The company's lead programs include bardoxolone methyl in Phase 3 trials for chronic kidney disease associated with Alport syndrome and pulmonary arterial hypertension, omaveloxolone in Phase 2 development for Friedreich's ataxia, and multiple Phase 2 programs targeting various forms of chronic kidney disease. Reata also has investigational compounds RTA 901 for neurological diseases and RTA 1701 for autoimmune, inflammatory, and fibrotic conditions, along with commercial access to bardoxolone for autosomal dominant polycystic kidney disease. The company has established strategic partnerships with Kyowa Kirin for bardoxolone development across Asia-Pacific markets and with AbbVie for next-generation Nrf2 activators in non-renal indications. Based in Plano, Texas, Reata was incorporated in 2002 and focuses on addressing unmet medical needs through targeted therapeutic innovation.
